A supplemental application for Keytruda (pembrolizumab) received FDA approval on 2021-12-17. This approval, categorized as an efficacy supplement, was granted to the sponsor, Merck Sharp Dohme. The approval signifies an update to the drug's label based on demonstrated effectiveness.
Background
Pembrolizumab, also known by its brand name Keytruda, is a pharmaceutical product developed and sponsored by Merck Sharp Dohme. This specific event marks a supplemental approval focusing on the drug's efficacy, as indicated by the FDA's classification of the application as 'Efficacy'. Supplemental approvals are a mechanism for the FDA to update a drug's existing approval with new information, such as additional indications, changes in dosing, or new patient populations.
What this means
This supplemental FDA approval for Keytruda (pembrolizumab), specifically categorized for efficacy, indicates an expansion or modification of the drug's approved uses or an update to its existing label based on new clinical data demonstrating effectiveness. While the precise new indication or patient population for which this efficacy approval was granted is not detailed in the provided source information, such approvals typically allow clinicians to prescribe the drug for a broader range of conditions or in new treatment settings where its effectiveness has been demonstrated. For healthcare providers and patients, this generally means expanded therapeutic options and potentially improved access to pembrolizumab for additional clinical needs. It reflects ongoing research and development by Merck Sharp Dohme to broaden the utility of this important medication.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 125514 S-120, a supplemental application for Keytruda (pembrolizumab), was documented on 2021-12-17 on the accessdata.fda.gov website, under the 'Efficacy' class. The sponsor for this application was Merck Sharp Dohme.